Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients

Watanabe, Jun; Kobayashi, Kazuo; Umeda, Fumio; Yamauchi, Teruaki; Mimura, Kazuo; Nakashima, Naoki; Masakado, Mitsunori; Hiramatsu, Shinsuke; Nawata, Hajime

doi:10.1016/0168-8227(93)90018-z

Cited by 22 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from 24 studies published in 20 articles that investigated the association between APOE genotypes and statin therapy met the inclusion criteria. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] Two articles provided separate data for gender or statin dose. 15,24 Figure 1 presents a flowchart of retrieved and excluded studies, with the reasons for exclusion.…”

Section: Eligible Studiesmentioning

confidence: 99%

APOE gene polymorphisms and response to statin therapy

et al. 2009

View full text Add to dashboard Cite

Published studies investigating the role of APOE gene on lipid response (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides) to statin treatment have reported inconsistent results. A meta-analysis was conducted to estimate the lipid response to statin treatment among APOE genetic variants (e2 carriers, e3e3 homozygotes and e4 carriers). Twenty-four studies were included in the meta-analyses. The pooled mean reduction (Dm) in TC from baseline was significant for all variants (e2 carriers: Dm ¼ À27.7% (À32.5 to À22.8%), e3e3: Dm ¼ À25.3% (À28.0 to À22.6%) and e4 carriers: Dm ¼ À25.1% (À29.3 to À21.0%)). Significant changes in LDL-C, HDL-C and triglyceride levels were also noted for all genotypes, although these changes did not differ significantly among genotypic groups. There was significant heterogeneity among the studies. Given these non-significant effects of APOE genotypes on lipid responses, there is little reason to consider the use of APOE genetic testing for guiding treatment with statins.

show abstract

Section: Eligible Studiesmentioning

confidence: 99%

APOE gene polymorphisms and response to statin therapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…53,85,87,91,95,101,107,112 114,116,125 However, in studies conducted among Asians, e4 carriers were associated with a greater response, followed by the e2 carriers and e3 homozygotes ( Table 3.2). 118,122,124,125 In addition, in Asians, e2 carriers and e3e3 homozygotes had poorer responses than did Caucasians, indicating that ethnicity might mediate the association between Apo E and response to statin therapy.…”

Section: Ethnicitymentioning

confidence: 99%

“…The e2 carriers had a greater mean decrease in TC in studies with both short (less than 12 weeks) 85,87,91,[99][100][101]113,116,118,122,124 and long follow-ups. 53,83,95,107,114 The decrease was larger in the short follow-up studies.…”

Section: Duration Of Follow-upmentioning

confidence: 99%

“…83,85,95,100,101,107,[112][113][114]116,118,122,124,125 In the familial hyperlipidemia studies, the e2 allele was associated with the greatest response among the genetic subgroups. The e3e3 homozygotes had greater reductions in TC than did the e4 carriers.…”

Section: Familial Hyperlipidemiamentioning

confidence: 99%

“…On the basis of the dose of statin, five studies on pravastatin had extractable data for a meta-analysis. 83,100,107,114,122 Pravastatin studies were classified as high-dose (more than 20 mg) or low-dose (20 mg or less) for analysis. With pravastatin therapy, e4 carriers had the smallest pooled reduction in TC.…”

Section: Type Of Statinmentioning

confidence: 99%

See 2 more Smart Citations